David Piacquad

CIK: 0001602343

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)6 (60.0%)

Compensation grants

Other (G, F, J, C, D, …)4 (40.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

NMRA

Neumora Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (10 total)

NMRA
Neumora Therapeutics, Inc.
May 27, 2026
Award(A)
Stock Option (Right to Buy)
Direct
80K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
28.6K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Award(A)
Stock Option (Right to Buy)
Direct
46.5K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Award(A)
Stock Option (Right to Buy)
Direct
28.6K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Award(A)
Stock Option (Right to Buy)
Direct
80K shares-
NMRA
Neumora Therapeutics, Inc.
May 28, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
46.5K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
28.6K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Award(A)
Stock Option (Right to Buy)
Direct
46.5K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Award(A)
Stock Option (Right to Buy)
Direct
28.6K shares-
NMRA
Neumora Therapeutics, Inc.
Feb 13, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
46.5K shares-

		Type	Shares	Price		Ownership
May 27, 2026	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	80,000	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	28,571	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	46,455	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	28,571	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	80,000	-	-	Direct
May 28, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	46,455	-	-	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	28,571	-	-	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	46,455	-	-	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	28,571	-	-	Direct
Feb 13, 2025	NMRA Neumora Therapeutics, Inc.	Disposition(D) Stock Option (Right to Buy)	46,455	-	-	Direct

1-10 of 10 transactions

About Piacquad David

Piacquad David (SEC CIK 0001602343) files insider reports with the SEC as Director of Neumora Therapeutics, Inc. (NMRA).

Signal8 holds 3 ownership filings by Piacquad David, all Form 4s, filed between Feb 18, 2025 and May 29, 2026. Those filings report 10 transactions, from Feb 13, 2025 to May 27, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Piacquad David's filings is in WATERTOWN, MA.

Recent filings by Piacquad David

May 27, 2026: Grant or award of NMRA derivative securities (Form 4, code A).
May 28, 2025: Disposition to issuer transaction of NMRA derivative securities (Form 4, code D).
May 28, 2025: Grants or awards of NMRA derivative securities (3 lines, Form 4, code A).
May 28, 2025: Disposition to issuer transaction of NMRA derivative securities (Form 4, code D).
Feb 13, 2025: Disposition to issuer transaction of NMRA derivative securities (Form 4, code D).

Other insiders filing for Neumora Therapeutics, Inc. (NMRA)

How to read Form 4 transaction codes